

Medytox files BLA of botulinum toxin

30 August 2018 | News

If approved, the BTX product will be marketed locally by Medytox Taiwan, a joint venture between Medytox and Dynamic Medical Technologies, a Taiwanese medical equipment company with a specialty in aesthetic lasers.



Medytox has said that it has filed a biologics license application with the Taiwan Food and Drug Administration for the sale of its botulinum toxin Neuronox.

Neuronox, also known as Meditoxin in Korea, is Medytox's flagship product that treats glabella lines. If approved, the BTX product will be marketed locally by Medytox Taiwan, a joint venture between Medytox and Dynamic Medical Technologies, a Taiwanese medical equipment company with a specialty in aesthetic lasers.

Currently, Taiwan has approved only three type A BTX drugs: Allergan's Botox, France-based Ipsen's Dysport and Germany-based Merz's Xeomin.

Medytox had laid the groundwork for commercial launch of Neuronox by establishing Medytox Taiwan, a joint venture with Taipei-based Dynamic Medical Technologies in 2015. If Medytox receives sales approval, it will become the fourth company to release a BTX product after Allergan, Ipsen, and Merz.

According to a report published by Korea Trade-Investment Promotion Agency (KOTRA), Taiwan is a significant base in the Southeast Asian economic zone, and an important country to advance into the market controlled by overseas Chinese.